This is a teaching paper intended as a quick introduction to some of the key concepts in the design of pharmaceutical trials for those new to the industry. Since the first ‘modern’ randomized clinical trial was reported in 1948 by the Medical Research Council, clinical trials have become a central component in the assessment of new therapies. The primary objective of any clinical trial is to obtain an unbiased and reliable assessment of a given regimen response independent of any known or unknown prognostic factors. The essential principals of trial design can be thought of as the ABC of allocation at random, blinding and controlled. In addition, the three Rs of endpoint selection – representative, reliability and reproducibility – are relevant in this context. This paper briefly describes the basic concepts for clinical trials and highlights possible points to consider. It draws heavily on the principles highlighted in the International Conference on Harmonisation guidelines as well as recommendations in the CONSORT statement.
No takes yet. Share an insight, caveat, or question.
Julious et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: